Managing AFib and BTK Inhibitors: Balancing Risk



As evidence on the association between cancer and atrial fibrillation (AF) continues to grow, an understanding of the impact on cancer and AF epidemiology and presentation will be essential to improving the cardio-oncologic care of patients with cancer. To educate the medical community about the importance of assessing risk, monitoring, and managing AF and other cardiovascular risk factors for cancer patients, the ACC has created the Managing AFib and BTK Inhibitors: Balancing Risk initiative. This initiative will focus on treatment for chronic lymphocytic leukemia/lymphoma (CLL), which is associated with a higher incidence of atrial fibrillation, as a case study for balancing risk in AF and cancer management. Stay up to date on best practices to guide clinical decision making and improve management of patients with AF and cancer.




Patient Case Quiz | Cardiovascular Adverse Effects of Bruton's Tyrosine Kinase (BTK) Inhibitors I February 18, 2021  
A 66-year-old woman with Waldenstrom macroglobulinemia presents with progressive splenomegaly and fatigue. 


Patient Case Quiz | Management of Atrial Fibrillation in Patients Treated with Bruton's Tyrosine Kinase (BTK) Inhibitors I February 18, 2021  
A 70-year-old man with chronic lymphocytic leukemia (CLL) who started ibrutinib 3 months prior is referred from the hematology clinic to cardiology with new onset palpitations and dyspnea on exertion.